Jean-Paul Castaigne

This inventor holds 7 USPTO granted patents and 14 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Angiochem Inc., Conjuchem, Inc.. Active years: 2011-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Paul Castaigne. Retrieved from https://idiyas.com/inventor/jean-paul-castaigne

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 14)

% Patents Active = 57.1

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 46(Granted Patents)

Company Filing History:

Years Active: 2011-2021

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10980892 - Methods for the treatment of leptomeningeal carcinomatosis (2021-04-20),

2. 9914754 - Conjugates of neurotensin or neurotensin analogs and uses thereof (2018-03-13),

3. 9173891 - Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog (2015-11-03),

4. 9161988 - Multimeric peptide conjugates and uses thereof (2015-10-20),

5. 8921314 - Conjugates of GLP-1 agonists and uses thereof (2014-12-30),

6. 8710013 - Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use (2014-04-29),

7. 8039432 - Method of treatment of diabetes and/or obesity with reduced nausea side effect (2011-10-18),

Title: The Innovative Mind of Jean-Paul Castaigne

Introduction

Jean-Paul Castaigne, based in Mont-Royal, Canada, is a prolific inventor known for his contributions to medical technologies and therapeutic methods. With a total of seven patents to his name, his work stands at the intersection of medicine and innovation, directly addressing critical health issues.

Latest Patents

Among his recent innovations, Castaigne has developed significant methods for treating leptomeningeal carcinomatosis. This invention utilizes a peptide-therapeutic conjugate exemplified by the agent ANG1005, showcasing his ability to pioneer new treatments for challenging medical conditions. Another prominent invention involves novel compounds characterized by the formula A-X-B, where A is a peptide vector enhancing transport across the blood-brain barrier, X serves as a linker, and B is a peptide therapeutic, such as neurotensin or its analogs. These compounds are designed to treat diseases where increased neurotensin activity is beneficial, and can also induce hypothermia or analgesia.

Career Highlights

Castaigne's career has been marked by his association with notable companies such as Angiochem Inc. and Conjuchem Inc., where he refined his expertise in therapeutic conjugates and drug delivery systems. His entrepreneurial spirit and innovative mindset have contributed significantly to advancements in biomedicine.

Collaborations

Throughout his career, Castaigne has collaborated with prominent colleagues including Michel Demeule and Betty Lawrence. These partnerships highlight his commitment to working within a collaborative environment to drive progress in healthcare technology.

Conclusion

Jean-Paul Castaigne continues to make significant strides in the field of medical invention, underscoring the importance of innovation in addressing complex health challenges. His patents not only reflect his expertise but also pave the way for potential breakthroughs in treatment methodologies for debilitating conditions.

Profile summary based on public USPTO records.